» COVID-19 Information


Manage your account, request prescriptions, set up appointments & more.

Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label



Clinical Trial Title

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Trial Status

Open to Enrollment

Start Date

October 25, 2017

Trial Type

Cancer - Adult Oncology

Specific Condition

Grade II Meningioma


This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.

Eligibility Criteria

  • Histologically confirmed diagnosis of WHO grade II meningioma confirmed by central pathology review
  • Age ≥ 18
  • Post-operative Zubrod Performance Status 0-1 within 60 days
  • History/physical examination, including neurologic examination within 60 days
  • If the patient is a woman is of childbearing potential, a serum pregnancy test, obtained within 14 days

Ineligibility Criteria

  • Optic nerve sheath meningioma, spinal or other extracranial meningioma, multiple meningiomas, hemangiopericytoma
  • Definitive evidence of metastatic meningioma
  • Prior invasive malignancy unless disease free for a minimum of 3 years
  • Previous radiotherapy to the scalp, cranium, brain, or skull base and radiation-induced meningiomas
  • Inability to undergo MRI with and without contrast

Please contact Legacy Oncology Research for additional study inclusion/exclusion information


IRB Number

Central IRB

Principal Investigator Name

Andrew Kee, MD

Contact Name

Oncology Clinical Research



Contact Fax


Contact E-Mail


Last Updated: Wednesday, January 27, 2021 12:56:50 PM